Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604120 | 1.00 | BACE1 (0.86) | BACE1BACE2 | |
| SCHEMBL25915985 | 0.93 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL14258641 | 0.91 | BACE1 (0.81) | BACE1BACE2 | |
| SCHEMBL4883151 | 0.90 | BACE1 (0.88) | BACE1BACE2 | |
| SCHEMBL7609802 | 0.90 | BACE1 (0.88) | BACE1BACE2 | |
| SCHEMBL7607163 | 0.89 | BACE1 (0.84) | BACE1BACE2 | |
| SCHEMBL4890341 | 0.89 | BACE1 (0.84) | BACE1BACE2 | |
| SCHEMBL7603646 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL4888346 | 0.89 | BACE1 (1.00) | BACE1BACE2 | |
| SCHEMBL4890158 | 0.89 | BACE1 (0.85) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265849-B1 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-10-25 | — | — | EP | claimed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | claimed |
| US-6737420-B2 | A SUBSTITUTED HYDROXYETHYLENE COMPOUND USEFUL FOR TREATING ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, DOWN'S SYNDROME, HEREDIATARY CEREBRAL HEMMORRHAGE WITH AMYLOIDOSIS, DEGENERATIVE DEMENTIA | ELAN PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | claimed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | claimed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | claimed |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | ELAN PHARMACEUTICALS, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2006-12-07 | — | — | US | disclosed |
| EP-1265849-B1 | COMPOUNDS AND METHODS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARM INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-7119085-B2 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-7030239-B2 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-6737420-B2 | A SUBSTITUTED HYDROXYETHYLENE COMPOUND USEFUL FOR TREATING ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT, DOWN'S SYNDROME, HEREDIATARY CEREBRAL HEMMORRHAGE WITH AMYLOIDOSIS, DEGENERATIVE DEMENTIA | ELAN PHARMACEUTICALS, INC. | 2004-05-18 | — | — | US | disclosed |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-21 | — | — | US | disclosed |
| US-20020019403-A1 | Methods to treat alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214846-A1 | Compounds to treat Alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 8/4885 |
| US-20060276642-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, BCHE | BACE1 5/4885BACE2 8/4885 |
| US-20020019403-A1 | Methods to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 9/4885 |
| US-20080058336-A1 | Methods to Treat Alzheimer's Disease | PSEN2, PSEN1, ACHE | BACE1 9/4885BACE2 8/4885 |
| US-20020022623-A1 | Compounds to treat alzheimer's disease | PSEN1, PSEN2, BACE1 | BACE1 3/4885BACE2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.